Citations

1. Williams CL, et al. (2002). Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation, 106(1): 143–160.

2. McSweeney JC, et al. (2003). Women's early warning symptoms of acute myocardial infarction. Circulation, 108(21): 2619–2623.

3. American Heart Association (2006). Heart disease and stroke statistics-2006 update. Circulation, 113(6): e85–e151.

4. Grundy SM (2001). United States cholesterol guidelines 2001: Expanded scope of intensive low-density lipoprotein-lowering therapy. American Journal of Cardiology, 88(7B): 23J–27J.

5. Snow V, et al. (2004). Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 141(7): 562–567. Also available online: http://www.annals.org/cgi/reprint/141/7/562.pdf.

6. U.S. Preventive Services Task Force, Agency for Healthcare and Research (2003). Screening for Diabetes Mellitus, Adult Type 2. Available online: http://www.ahrq.gov/clinic/uspstf/uspsdiab.htm.

7. Koenig W (2001). Inflammation and coronary artery disease: An overview. Cardiology in Review, 9(1): 31–35.

8. Pearson TA, et al. (2003). Markers of inflammation and cardiovascular disease: American Heart Association and the Centers for Disease Control and Prevention scientific statement. Circulation, 107(3): 499–511.

9. Goldenberg I, et al. (2003). Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Archives of Internal Medicine, 163(19): 2301–2305.

10. Silagy C, et al. (2006). Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews (1). Oxford: Update Software.

11. Hayden M, et al. (2002). Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 136(2): 161–172.

12. U.S. Preventive Services Task Force (2002). Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Annals of Internal Medicine, 136(2): 157–160.

13. Jolliffe JA, et al. (2006). Exercise-based rehabilitation for coronary heart disease. Cochrane Database of Systematic Reviews (1). Oxford: Update Software.

14. Grundy S, et al. (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (NIH Publication No. 02–5215). Bethesda, MD: National Institutes of Health. Also available online: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf.

15. Wang C, et al. (2004). Effects of Omega-3 Fatty Acids on Cardiovascular Disease. Evidence Report/Technology Assessment No. 94. (AHRQ Publication No. 04-E0009-2). Rockville, MD: Agency for Healthcare Research and Quality. Also available online: http://www.ahrq.gov/clinic/epcindex.htm#dietsup.

16. Sacks FM, et al. (2006). Soy protein, isoflavones, and cardiovascular health: An American Heart Association science advisory for professionals from the Nutrition Committee. Circulation, 113(7): 1034–1044. Also available online: http://circ.ahajournals.org/cgi/content/full/113/7/1034.

17. Herrington DM, et al. (2002). Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS). Circulation, 105(25): 2962–2967.

18. Rossouw JE, et al. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297(13): 1465–1477.

19. Bravata DM, et al. (2003). Efficacy and safety of low-carbohydrate diets: A systematic review. JAMA, 289(14): 1837–1850.

20. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006). Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine, 354(15): 1567–1577.

21. Foster C, et al. (2004). Cardiovascular disorders: Primary prevention. Clinical Evidence (12): 159–192.

22. U.S. Food and Drug Administration (2006). Concomitant use of ibuprofen and aspirin: Potential for attenuation of the anti-platelet effect of aspirin. Food and Drug Administration Science Paper. September 8, 2006. Available online: http://www.fda.gov/cder/drug/infopage/ibuprofen/science_paper.htm.

23. Smith SC Jr, et al. (2006). ACC/AHA/SCAI 2005 guidelines update for percutaneous coronary intervention: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation, 113(1): 156–175.

24. Gami A (2006). Secondary prevention of ischaemic cardiac events, search date July 2004. Online version of Clinical Evidence (15): 1–31.

25. Morice M (2002). A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. New England Journal of Medicine, 346(23): 1773–1780.

Other Works Consulted

• American Heart Association and American College of Cardiology (2006). AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation, 113(19): 2363–2372. [Erratum in Circulation, 113(22): 847.]

• Mosca L, et al. (2004). American Heart Association: Evidence-based guidelines for cardiovascular disease prevention in women. Circulation, 109(5): 672–693.